This decrease in the inflammatory responses might elicit beneficial effects during viral infections, as previously reported with other RANK-L inhibitors [19], and could explain the decreased incidence of COVID-19 cases among patients treated with denosumab. Here, TNFSF11 is linked to COVID-19.